Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3- methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1- (2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
Methods of treating, preventing or managing antecedent hematologic disorders,such as myelodysplastic syndrome, including chronic myelomonocytic leukemiaare disclosed. The methods encompass the administration of SNS-595. Also providedare methods of treatment using this compound with chemotherapy, radiation therapy,hormonal therapy, biological therapy or immunotherapy. In certain embodiments,the method of treatment comprise administering SNS-595 in combination withcytarabine. Pharmaceutical compositions and single unit dosage forms suitablefor use in the methods are also disclosed.
